Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

Background Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has
shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We report …

Background Vedolizumab, a gut‐selective α4β7 integrin antibody, is approved for
moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Aim To report …

Abstract Background and Aims Vedolizumab is a gut-selective antibody to α 4 β 7 integrin,
approved to treat moderate-to-severe ulcerative colitis and Crohn's disease in adults …

The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the
treatment of inflammatory bowel disease (IBD). However, some patients experience primary …

Vedolizumab is a humanized anti-α 4 β 7 integrin monoclonal antibody that selectively
blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α 4 β 7-mucosal …

Background We recently showed that vedolizumab is effective in patients with Crohn's
disease (CD) and ulcerative colitis (UC) with prior anti‐TNF failure in a multicentre …

Background Effectiveness of vedolizumab in real world clinical practice is unknown. Aim To
evaluate the short and long‐term effectiveness of vedolizumab in patients with inflammatory …

Objectives: Clinical trials have demonstrated the efficacy of vedolizumab in inflammatory
bowel disease (IBD). However, these findings may not reflect the clinical practice. Therefore …

Background & Aims Phase 3 trials have shown the efficacy of vedolizumab, which binds to
integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We …